KVP Capital Advisors, LP
CIK 1858198 · View on SEC EDGAR ↗
- Portfolio value
- $136.2M
- Positions
- 35
- As of
- June 30, 2026
#7,684 of 9,443 by 13F value · top 81.4%
Portfolio value QoQ: +1.7% 13F does not disclose cash
- Top 10 holdings weight
- 57.41%
- Top 25 holdings weight
- 89.22%
- Positions above 1%
- 32
- Effective number of positions
- 22.2
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 13.86% Est. buys $18,714,663 · sells $37,982,560
- New positions
- 6
- Increased
- 2
- Decreased
- 2
- Closed
- 3
On this page
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Sector breakdown
Healthcare
100.0%
Full portfolio 35 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. - Common Stock | $14,362,491 | 10.54% | 42,900 | $540,540 | |||
| WHWK Whitehawk Therapeutics, Inc. - Common Stock | $9,920,266 | 7.28% | 2,165,997 | $2,447,576 | |||
| ERAS Erasca, Inc. - Common Stock | $8,335,600 | 6.12% | 455,000 | $2,834,400 | Up ×1 | ||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $7,721,100 | 5.67% | 414,000 | $2,782,080 | |||
| STRO Sutro Biopharma, Inc. - Common Stock | $7,522,290 | 5.52% | 226,575 | $1,878,307 | |||
| TNGX Tango Therapeutics, Inc. - Common Stock | $7,198,053 | 5.28% | 230,264 | $2,380,930 | |||
| MBX MBX Biosciences, Inc. - Common Stock | $6,708,125 | 4.92% | 121,524 | $3,080,634 | |||
| PTGX Protagonist Therapeutics, Inc. - Common Stock | $6,496,740 | 4.77% | 53,000 | $910,540 | |||
| EWTX Edgewise Therapeutics, Inc. - Common Stock | $5,403,790 | 3.97% | 133,000 | $1,214,290 | |||
| TNDM Tandem Diabetes Care, Inc. - Common Stock | $4,542,090 | 3.33% | 301,000 | Up ×1 | |||
| IRON Disc Medicine, Inc. - Common Stock | $4,260,405 | 3.13% | 58,250 | $535,900 | |||
| SVRA Savara, Inc. - Common Stock | $3,728,525 | 2.74% | 605,280 | $423,696 | |||
| AVBP ArriVent BioPharma, Inc. - Common Stock | $3,543,480 | 2.60% | 102,000 | Up ×1 | |||
| INSM Insmed Incorporated - Common Stock | $3,038,350 | 2.23% | 28,497 | $-1,621,479 | |||
| ACHV Achieve Life Sciences, Inc. - Common Shares | $3,019,178 | 2.22% | 462,355 | $1,659,854 | |||
| IDYA IDEAYA Biosciences, Inc. - Common Stock | $2,970,419 | 2.18% | 79,700 | $314,815 | |||
| OCUL Ocular Therapeutix, Inc. - Common Stock | $2,946,000 | 2.16% | 300,000 | $405,000 | |||
| AXSM Axsome Therapeutics, Inc. - Common Stock | $2,937,240 | 2.16% | 12,000 | $-3,181,284 | Down ×1 | ||
| DSGN Design Therapeutics, Inc. - Common Stock | $2,676,950 | 1.96% | 185,000 | Up ×1 | |||
| UTHR United Therapeutics Corporation - Common Stock | $2,573,693 | 1.89% | 4,750 | $-242,962 | |||
| SRRK Scholar Rock Holding Corporation - Common Stock | $2,475,000 | 1.82% | 45,000 | $262,800 | |||
| IMMX Immix Biopharma, Inc. - Common Stock | $2,375,661 | 1.74% | 230,423 | $276,507 | |||
| VRDN Viridian Therapeutics, Inc. - Common Stock | $2,296,250 | 1.69% | 125,000 | $-148,750 | |||
| MLYS Mineralys Therapeutics, Inc. - Common Stock | $2,270,853 | 1.67% | 84,168 | Up ×1 | |||
| DRUG Bright Minds Biosciences Inc. - common stock | $2,233,273 | 1.64% | 31,813 | $-88,122 | |||
| TVTX Travere Therapeutics, Inc. - Common Stock | $2,215,590 | 1.63% | 39,000 | $-488,020 | Down ×1 | ||
| ZURA Zura Bio Limited - Class A Ordinary shares | $2,201,455 | 1.62% | 373,128 | $-18,657 | |||
| ARTV Artiva Biotherapeutics, Inc. - Common Stock | $1,940,000 | 1.42% | 200,000 | Up ×1 | |||
| NKTR Nektar Therapeutics - Common Stock | $1,877,889 | 1.38% | 26,900 | $-57,566 | |||
| CMPX Compass Therapeutics, Inc. - Common Stock | $1,688,490 | 1.24% | 771,000 | $-956,510 | Up ×1 | ||
| CABA Cabaletta Bio, Inc. - Common Stock | $1,571,890 | 1.15% | 505,431 | $212,281 | |||
| VERA Vera Therapeutics, Inc. - Class A Common Stock | $1,403,157 | 1.03% | 32,700 | $87,636 | |||
| EOLS Evolus, Inc. - Common Stock | $1,041,000 | 0.76% | 150,000 | Up ×1 | |||
| CELC Celcuity Inc. - Common Stock | $418,480 | 0.31% | 4,000 | $-38,080 | |||
| VYNE VYNE Therapeutics Inc. - Common Stock | $325,709 | 0.24% | 500,551 | $26,630 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| AXSM | Trimmed | -24K | -$3.2M |
| MBX | Price move only | +0 | +$3.1M |
| ERAS | Bought more | +115K | +$2.8M |
| TRVI | Price move only | +0 | +$2.8M |
| WHWK | Price move only | +0 | +$2.4M |
| TNGX | Price move only | +0 | +$2.4M |
| STRO | Price move only | +0 | +$1.9M |
| ACHV | Price move only | +0 | +$1.7M |
| INSM | Price move only | +0 | -$1.6M |
| EWTX | Price move only | +0 | +$1.2M |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| TERN | June 30, 2026 | 440,000 | $23,196,800 | No longer tracked |
| RVMD | June 30, 2026 | 40,200 | $3,909,450 | 13.4% |
| JAZZ | March 31, 2026 | 17,500 | $2,975,000 | 32.4% |
| SLNO | June 30, 2026 | 59,700 | $1,998,756 | No longer tracked |
| FULC | March 31, 2026 | 50,000 | $565,500 | -49.4% |